Volume 12 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(1): 37-42
Ma Maolin, Shi Bingyi, Sun Qiquan. Interpretation of latest literatures on renal transplantation in the third quarter of 2020[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 37-42. doi: 10.3969/j.issn.1674-7445.2021.01.006
Citation: Ma Maolin, Shi Bingyi, Sun Qiquan. Interpretation of latest literatures on renal transplantation in the third quarter of 2020[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 37-42. doi: 10.3969/j.issn.1674-7445.2021.01.006
shu

Interpretation of latest literatures on renal transplantation in the third quarter of 2020

doi: 10.3969/j.issn.1674-7445.2021.01.006

  • Department of Renal Transplantation, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Sun Qiquan, Email: sunqiq@mail.sysu.edu.cn
  • Received Date: 2020-12-03
    Available Online: 2021-01-19
  • Publish Date: 2021-01-19
    Abstract
  • How to improve the long-term prognosis of transplant kidney and solve the shortage of donor kidney are still two major problems that plague clinicians. Among them, ischemia-reperfusion injury (IRI), rejection, infection, and immunosuppressive therapy are important issues in the research field of renal transplantation. Therefore, strengthening the literature study in the field of renal transplantation and understanding the nature of transplant kidney related diseases and international frontier research hotspots, help to further improve the function and prolong the survival time of the transplant kidney in clinic. This article interpreted literatures on the research hotspots and new progress in the field of renal transplantation in the third quarter of 2020, combined with the meeting minutes of the 12th Lingnan Reading Club, and reviewed from the three aspects of IRI, rejection and infection.

     

    • FullText(HTML)
  • loading
    • References(36)
  • [1]
    SALVADORI M, ROSSO G, BERTONI E. Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment[J]. World J Transplant, 2015, 5(2):52-67. DOI: 10.5500/wjt.v5.i2.52.
    [2]
    PERICO N, CATTANEO D, SAYEGH MH, et al. Delayed graft function in kidney transplantation[J]. Lancet, 2004, 364(9447):1814-1827. DOI: 10.1016/S0140-6736(04)17406-0.
    [3]
    LEFER DJ, BOLLI R. Development of an NIH consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation[J]. J Cardiovasc Pharmacol Ther, 2011, 16(3/4):332-339. DOI: 10.1177/1074248411414155.
    [4]
    CAVAILLÉ-COLL M, BALA S, VELIDEDEOGLU E, et al. Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation[J]. Am J Transplant, 2013, 13(5):1134-1148. DOI: 10.1111/ajt.12210.
    [5]
    LINDEMAN JH, WIJERMARS LG, KOSTIDIS S, et al. Results of an explorative clinical evaluation suggest immediate and persistent post-reperfusion metabolic paralysis drives kidney ischemia reperfusion injury[J]. Kidney Int, 2020, 98(6):1476-1488. DOI:10.1016/j.kint. 2020.07.026.
    [6]
    FONTANA L, PARTRIDGE L, LONGO VD. Extending healthy life span--from yeast to humans[J]. Science, 2010, 328(5976):321-326. DOI: 10.1126/science.1172539.
    [7]
    VERMEIJ WP, DOLLÉ ME, REILING E, et al. Restricted diet delays accelerated ageing and genomic stress in DNA-repair-deficient mice[J]. Nature, 2016, 537(7620):427-431. DOI: 10.1038/nature19329.
    [8]
    JONGBLOED F, DE BRUIN RWF, STEEG HV, et al. Protein and calorie restriction may improve outcomes in living kidney donors and kidney transplant recipients[J]. Aging (Albany NY), 2020, 12(13):12441-12467. DOI: 10.18632/aging.103619.
    [9]
    THOMPSON ER, BATES L, IBRAHIM IK, et al. Novel delivery of cellular therapy to reduce ischemia reperfusion injury in kidney transplantation[J]. Am J Transplant, 2020, DOI: 10.1111/ajt.16100[Epub ahead of print].
    [10]
    STEICHEN C, ERPICUM P. Combining cell-based therapy and normothermic machine perfusion for kidney graft conditioning has gone one step further[J]. Am J Transplant, 2020, DOI: 10.1111/ajt.16260[Epub ahead of print].
    [11]
    JANSEN MPB, PULSKENS WPC, UIL M, et al. Urinary mitochondrial DNA associates with delayed graft function following renal transplantation[J]. Nephrol Dial Transplant, 2020, 35(8):1320-1327. DOI: 10.1093/ndt/gfy372.
    [12]
    VAN DER ZWAN M, CLAHSEN-VAN GRONINGEN MC, VAN DEN HOOGEN MWF, et al. Comparison of alemtuzumab and anti-thymocyte globulin treatment for acute kidney allograft rejection[J]. Front Immunol, 2020, 11:1332. DOI: 10.3389/fimmu.2020.01332.
    [13]
    SELLARÉS J, DE FREITAS DG, MENGEL M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence[J]. Am J Transplant, 2012, 12(2):388-399. DOI: 10.1111/j.1600-6143.2011.03840.x.
    [14]
    JOHNSON RK, SARMARAPUNGAVAN D, PARASURAMAN RK, et al. Acute tubular injury is an important component in type Ⅰ acute antibody-mediated rejection[J]. Transplant Proc, 2013, 45(9):3262-3268. DOI: 10.1016/j.transproceed.2013.05.012.
    [15]
    CLOTET-FREIXAS S, MCEVOY CM, BATRUCH I, et al. Extracellular matrix injury of kidney allografts in antibody-mediated rejection: a proteomics study[J].J Am Soc Nephrol, 2020, 31(11):2705-2724. DOI: 10.1681/ASN.2020030286.
    [16]
    WIEBE C, RUSH DN, GIBSON IW, et al. Evidence for the alloimmune basis and prognostic significance of borderline T cell-mediated rejection[J]. Am J Transplant, 2020, 20(9):2499-2508. DOI: 10.1111/ajt.15860.
    [17]
    SENEV A, COEMANS M, LERUT E, et al. Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: an observational cohort study[J]. J Am Soc Nephrol, 2020, 31(9):2193-2204. DOI: 10.1681/ASN.2020010019.
    [18]
    MORATH C, DÖHLER B, KÄLBLE F, et al. Pre-transplant HLA antibodies and delayed graft function in the current era of kidney transplantation[J]. Front Immunol, 2020, 11:1886. DOI: 10.3389/fimmu.2020.01886.
    [19]
    SHISHIDO S, ASANUMA H, NAKAI H, et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy[J]. J Am Soc Nephrol, 2003, 14(4):1046-1052. DOI: 10.1097/01.asn.0000056189.02819.32.
    [20]
    KUYPERS DR. Immunosuppressive drug therapy and subclinical acute renal allograft rejection: impact and effect[J]. Transplantation, 2008, 85(7 Suppl):S25-S30. DOI: 10.1097/TP.0b013e318169c48d.
    [21]
    HEILMAN RL, DEVARAPALLI Y, CHAKKERA HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients[J]. Am J Transplant, 2010, 10(3):563-570. DOI: 10.1111/j.1600-6143.2009.02966.x.
    [22]
    NANKIVELL BJ. The meaning of borderline rejection in kidney transplantation[J]. Kidney Int, 2020, 98(2):278-280. DOI: 10.1016/j.kint.2020.04.052.
    [23]
    O'CONNELL PJ, ZHANG W, MENON MC, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study[J]. Lancet, 2016, 388(10048):983-993. DOI: 10.1016/S0140-6736(16)30826-1.
    [24]
    YI Z, KEUNG KL, LI L, et al. Key driver genes as potential therapeutic targets in renal allograft rejection[J]. JCI Insight, 2020, 5(15):e136220. DOI: 10.1172/jci.insight.136220.
    [25]
    NAIR V, JANDOVITZ N, HIRSCH JS, et al. COVID-19 in kidney transplant recipients[J]. Am J Transplant, 2020, 20(7):1819-1825. DOI: 10.1111/ajt.15967.
    [26]
    KRONBICHLER A, GAUCKLER P, WINDPESSL M, et al. COVID-19: implications for immunosuppression in kidney disease and transplantation[J]. Nat Rev Nephrol, 2020, 16(7):365-367. DOI: 10.1038/s41581-020-0305-6.
    [27]
    ABRISHAMI A, SAMAVAT S, BEHNAM B, et al. Clinical course, imaging features, and outcomes of COVID-19 in kidney transplant recipients[J]. Eur Urol, 2020, 78(2):281-286. DOI: 10.1016/j.eururo.2020.04.064.
    [28]
    FAGUER S, DEL BELLO A, ABRAVANEL F, et al. Tocilizumab for hemophagocytic syndrome in a kidney transplant recipient with COVID-19[J]. Ann Intern Med, 2020, 173(6):501-503. DOI: 10.7326/L20-0419.
    [29]
    SOLIS M, VELAY A, PORCHER R, et al. Neutralizing antibody-mediated response and risk of BK virus-associated nephropathy[J]. J Am Soc Nephrol, 2018, 29(1):326-334. DOI: 10.1681/ASN.2017050532.
    [30]
    SAWINSKI D, GORAL S. BK virus infection: an update on diagnosis and treatment[J]. Nephrol Dial Transplant, 2015, 30(2):209-217. DOI: 10.1093/ndt/gfu023.
    [31]
    CHEN XT, CHEN WF, LI J, et al. Urine donor-derived cell-free DNA helps discriminate BK polyomavirus-associated nephropathy in kidney transplant recipients with BK polyomavirus infection[J]. Front Immunol, 2020, 11:1763. DOI: 10.3389/fimmu.2020.01763.
    [32]
    HUANG Y, CHEN XT, YANG SC, et al. Detection of proximal tubule involvement by BK polyomavirus in kidney transplant recipients with urinary sediment double-immunostaining[J]. Front Immunol, 2020, 11:582678. DOI: 10.3389/fimmu.2020.582678.
    [33]
    DOBERER K, SCHIEMANN M, STRASSL R, et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients-a prospective observational trial[J]. Am J Transplant, 2020, 20(8):2081-2090. DOI: 10.1111/ajt.15810.
    [34]
    FERNÁNDEZ-RUIZ M. Torque teno virus load as a surrogate marker for the net state of immunosuppression: the beneficial side of the virome[J]. Am J Transplant, 2020, 20(8):1963-1964. DOI: 10.1111/ajt.15872.
    [35]
    SISE ME, GOLDBERG DS, KORT JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection[J]. J Am Soc Nephrol, 2020, 31(11):2678-2687. DOI: 10.1681/ASN.2020050686.
    [36]
    COUSSEMENT J, KAMAR N, MATIGNON M, et al. Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial[J]. Clin Microbiol Infect, 2020, DOI: 10.1016/j.cmi.2020.09.005[Epub ahead of print].
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (247) PDF downloads(53) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return